Clinical Trials Arena January 13, 2025
GlobalData Healthcare

The popularity of GLP-1R drugs has catapulted the treatment landscape of obesity into the spotlight.

There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of Novo Nordisk’s GLP-1R obesity drug, Wegovy, has ignited a surge in innovator drug obesity trials. Companies are hoping to disrupt the space and loosen the stronghold that Novo Nordisk and Eli Lily, whose obesity drugs accounted for 99% of the $37.2bn GLP-1R sales in 2023, have on the market.

The popularity of GLP-1R drugs has catapulted the treatment landscape of obesity into the spotlight. Reformation for the management of this disease is long overdue considering obesity was only recognised as a disease by the American...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Related Articles:
Carta Healthcare to Power Oncology Research and Clinical Trials with Acquisition of Realyze Intelligence, a UPMC Enterprises Company
Rubicon Founders Invests $165M in Caidya to Fuel Global Expansion
FDA warns of “important” clinical trial protocol deviations
Unlocking peak operational performance in clinical development with artificial intelligence
Drug extends survival in lung cancer patients: J&J

Share This Article